These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26062687)

  • 1. [Hyperkalemia : what can we expect from new potassium-lowering drugs?].
    Schmitt R
    Internist (Berl); 2015 Jul; 56(7):779-83. PubMed ID: 26062687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.
    Meaney CJ; Beccari MV; Yang Y; Zhao J
    Pharmacotherapy; 2017 Apr; 37(4):401-411. PubMed ID: 28122118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium zirconium cyclosilicate (Lokelma) for hyperkalemia.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):197-199. PubMed ID: 30653476
    [No Abstract]   [Full Text] [Related]  

  • 4. New drugs to prevent and treat hyperkalemia.
    Lepage L; Desforges K; Lafrance JP
    Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia.
    Linder KE; Krawczynski MA; Laskey D
    Pharmacotherapy; 2016 Aug; 36(8):923-33. PubMed ID: 27393581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Agents for the Prevention and Management of Hyperkalemia.
    McCullough PA; Costanzo MR; Silver M; Spinowitz B; Zhang J; Lepor NE
    Rev Cardiovasc Med; 2015; 16(2):140-55. PubMed ID: 26198561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
    Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies for the management of chronic hyperkalemia in the ambulatory care setting.
    Henneman A; Guirguis E; Grace Y; Patel D; Shah B
    Am J Health Syst Pharm; 2016 Jan; 73(2):33-44. PubMed ID: 26721532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy.
    Bridgeman MB; Shah M; Foote E
    Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii45-iii50. PubMed ID: 31800078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing Hyperkalemia: Stepping Into a New Frontier.
    Pham AQ; Sexton J; Wimer D; Rana I; Nguyen T
    J Pharm Pract; 2017 Oct; 30(5):557-561. PubMed ID: 27609505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential New Agents for the Management of Hyperkalemia.
    Packham DK; Kosiborod M
    Am J Cardiovasc Drugs; 2016 Feb; 16(1):19-31. PubMed ID: 26156040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patiromer: a clinical review.
    Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
    Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
    Kosiborod M; Rasmussen HS; Lavin P; Qunibi WY; Spinowitz B; Packham D; Roger SD; Yang A; Lerma E; Singh B
    JAMA; 2014 Dec; 312(21):2223-33. PubMed ID: 25402495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia.
    Cases A; Gorriz JL
    Drugs Today (Barc); 2018 Oct; 54(10):601-613. PubMed ID: 30398481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders.
    Sarwar CMS; Bhagat AA; Anker SD; Butler J
    Handb Exp Pharmacol; 2017; 243():537-560. PubMed ID: 28382468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients.
    Sullivan E; Ruegger M; Dunne I; Sutaria N; Towers WF
    Am J Health Syst Pharm; 2023 Sep; 80(18):1238-1246. PubMed ID: 37335862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of sodium zirconium cyclosilicate: a new treatment option for hyperkalaemia in China.
    Lu Y; Liu BC; Liu H
    Expert Opin Pharmacother; 2023 Feb; 24(3):301-308. PubMed ID: 36617700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.